Table 2.

Preventive vaccination results

Vaccine Scenario	New HIV Infections	Incremental Costsb (billions)	Incremental QALYs b (millions)	ICER relative to:
Targeted Populationa				No vaccination	High-risk Vaccination
No Vaccination	1,286,009	---	---	---	---
75% Efficacy, Lifetime Duration, Price $1000
Universal Vaccination	373,757	$130.2	8.7	$15,010	$93,860
High-risk Group Vaccination	512,044	−$30.5	7.0	Cost-saving	---
50% Efficacy, Lifetime Duration, Price $1000
Universal Vaccination	613,121	$142.3	6.3	$22,435	$126,416
High-risk Group Vaccination	718,739	−$20.1	5.1	Cost-saving	---
75% Efficacy, 5-year Duration, Price $1000
Universal Vaccination	837,566	$152.7	4.4	$34,447	$193,080
High-risk Group Vaccination	902,169	−$11.7	3.6	Cost-saving	---
75% Efficacy, Lifetime Duration, Price $500
Universal Vaccination	373,757	$42.5	8.7	$4,893	$42,599
High-risk Group Vaccination	512,044	−$34.4	7.0	Cost-saving	---

Universal Vaccination = Vaccination of high-risk and low-risk groups.

ICER = Incremental cost-effectiveness ratio, relative to no vaccination or high-risk group vaccination.

Efficacy = Decrease in vaccinated individual’s chance of acquiring HIV.

Duration = Average length of protection conferred by preventive vaccine.

^aAll results in this table assume 75% vaccination coverage of the targeted population.

^bIncremental costs and quality-adjusted life years (QALYs) are relative to no vaccination.